RT Journal Article
SR Electronic
T1 Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.27.21262754
DO 10.1101/2021.08.27.21262754
A1 Stankiewicz Karita, Helen C.
A1 Dong, Tracy Q.
A1 Johnston, Christine
A1 Neuzil, Kathleen M.
A1 Paasche-Orlow, Michael K.
A1 Kissinger, Patricia J.
A1 Bershteyn, Anna
A1 Thorpe, Lorna E.
A1 Deming, Meagan
A1 Kottkamp, Angelica
A1 Laufer, Miriam
A1 Landovitz, Raphael J.
A1 Luk, Alfred
A1 Hoffman, Risa
A1 Roychoudhury, Pavitra
A1 Magaret, Craig A.
A1 Grenninger, Alexander L.
A1 Huang, Meei-Li
A1 Jerome, Keith R.
A1 Wener, Mark
A1 Celum, Connie
A1 Chu, Helen Y.
A1 Baeten, Jared M.
A1 Wald, Anna
A1 Barnabas, Ruanne V.
A1 Brown, Elizabeth R.
A1 the Hydroxychloroquine COVID-19 PEP Study Team
YR 2021
UL http://medrxiv.org/content/early/2021/08/31/2021.08.27.21262754.abstract
AB Importance SARS-CoV-2 viral trajectory has not been well-characterized in documented incident infections. These data will inform SARS-CoV-2 natural history, transmission dynamics, prevention practices, and therapeutic development.Objective To prospectively characterize early SARS-CoV-2 viral shedding in persons with incident infection.Design Prospective cohort study.Setting Secondary data analysis from a multicenter study in the U.S.Participants The samples derived from a randomized controlled trial of 829 community-based asymptomatic participants recently exposed (<96 hours) to persons with SARS-CoV-2. Participants collected daily mid-turbinate swabs for SARS-CoV-2 detection by polymerase-chain-reaction and symptom diaries for 14-days. Persons with negative swab for SARS-CoV-2 at baseline who developed infection during the study were included in the analysis.Exposure Laboratory-confirmed SARS-CoV-2 infection.Main outcomes and measures The observed SARS-CoV-2 viral shedding characteristics were summarized and shedding trajectories were examined using a piece-wise linear mixed-effects modeling. Whole viral genome sequencing was performed on samples with cycle threshold (Ct)<34.Results Ninety-seven persons (57% women, median age 37-years) developed incident infections during 14-days of follow-up. Two-hundred fifteen sequenced samples were assigned to 15 lineages that belonged to the G614 variant. Forty-two (43%), 18(19%), and 31(32%) participants had viral shedding for 1 day, 2-6 days, and ≥7 days, with median peak viral load Ct of 38.5, 36.7, and 18.3, respectively. Six (6%) participants had 1–6 days of observed viral shedding with censored duration. The peak average viral load was observed on day 3 of viral shedding. The average Ct value was lower, indicating higher viral load, in persons reporting COVID-19 symptoms than asymptomatic. Using the statistical model, the median time from shedding onset to peak viral load was 1.4 days followed by a median of 9.7 days before clearance.Conclusions and Relevance Incident SARS-CoV-2 G614 infection resulted in a rapid viral load peak followed by slower decay and positive correlation between peak viral load and shedding duration; duration of shedding was heterogeneous. This longitudinal evaluation of the SARS-CoV-2 G614 variant with frequent molecular testing may serve as a reference for comparing emergent viral lineages to inform clinical trial designs and public health strategies to contain the spread of the virus.Question What are the early SARS-CoV-2 G614 viral shedding characteristics in persons with incident infection?Findings In this prospective cohort of 97 community-based participants who collected daily mid-turbinate swabs for SARS-CoV-2 detection after recent exposure to SARS-CoV-2, viral trajectory was characterized by a rapid peak followed by slower decay. Peak viral load correlated positively with symptoms. The duration of shedding was heterogeneous.Meaning A detailed description of the SARS-CoV-2 G614 viral shedding trajectory serves as baseline for comparison to new viral variants of concern and inform models for the planning of clinical trials and transmission dynamics to end this pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPrimary funding source: Bill & Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Western Institutional Review Board approved the trial; all participants provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data are available from the corresponding author on request.